- BGI Group responds to coronavirus crisis by providing reagent
kits for molecular 2019-nCoV testing by next-generation sequencing
and RT-PCR
- Ares Genetics to launch next-generation sequencing testing
service for infection control and monitoring of 2019-nCoV evolution
using BGI Group reagents
- Ares Genetics, Curetis Group and BGI Group to collaborate in
the distribution of next-generations sequencing and PCR testing
kits for 2019-nCoV
Vienna, Austria, Holzgerlingen, Germany,
and Shenzhen, China, January 30, 2020, 08:00 am CET - Ares
Genetics GmbH, a Curetis Group company, and the Chinese genomics
company BGI Group today announced that the companies will
collaborate in making molecular testing for the new coronavirus
2019-nCoV available in Europe.
2019-nCoV is a new coronavirus variant that has
not been previously identified in humans but is responsible for the
outbreak originating in the Chinese city of Wuhan and currently
rapidly spreading globally with first cases identified and
confirmed in Europe already. In response to this situation, and
immediately after the occurrence of unexplained pneumonia in Wuhan,
BGI sequenced the genome of the new 2019-nCoV virus and
successfully developed a Real-Time (RT) Fluorescent PCR
(polymerase chain reaction) kit for detecting 2019-nCoV, which can
provide results in a few hours and has already obtained approval by
the Chinese National Medical Products Administration.
In addition to the rapid detection kit based on
RT-PCR technology, the DNBSEQ-T7 sequencing platform developed by
the BGI Group company MGI passed the emergency approval procedure
of the National Medical Products Administration, becoming the first
officially approved testing products in China for surveillance,
discovery and identification of unknown infectious diseases.
In Europe, BGI and MGI will work with their
long-term strategic partner Ares Genetics to make its 2019-nCoV
testing portfolio available to public health institutions and
hospitals for outbreak monitoring, infection control, and
epidemiology. Ares Genetics expects to provide next-generation
sequencing services for 2019-nCoV out of its NGS laboratory in
Vienna Austria for infection control and tracking of pathogen
evolution from February 2020 onwards based on MGI’s DNBSEQ
sequencing platform. Further, Ares Genetics and the Curetis Group
will support BGI Group in the distribution of its PCR and NGS
reagent kits to molecular testing laboratories in Europe that have
the capability for 2019-nCoV testing with reagent kits initially
being marketed for research use only prior to regulatory approval
in Europe.
Ares Genetics is a digital diagnostics company
utilizing artificial intelligence-powered molecular diagnostics to
advance the field of infectious disease testing. Ares Genetics
recently launched ARESupa – Universal Pathogenome Assay for the
broad identification of bacterial pathogens and the accurate
prediction of antibiotic susceptibility. The ARESupa test is based
on the sequencing of bacterial DNA, combined with data analysis and
interpretation powered by ARESdb, Ares Genetics’ unique,
proprietary reference database on genetic antimicrobial resistance
markers. The first generation of ARESupa is currently offered for
non-diagnostic applications in epidemiology, infection control, and
outbreak analysis for customers in the public health sector and the
pharmaceutical industry. A laboratory-developed test (LDT) for
human diagnostic use is under development.
“The ability to rapidly test for 2019-nCoV with
PCR as well as track its evolution by next-generation sequencing is
key to contain this global outbreak. While Ares Genetics
specializes in molecular detection of bacterial pathogens and
antibiotic susceptibility prediction, we are responding to the
global coronavirus health threat via our specialized molecular
service laboratory and making 2019-nCoV testing broadly available
in Europe under our strategic partnership with BGI.” commented Dr.
Andreas Posch, Managing Director and CEO of Ares Genetics,
“Longer-term, we anticipate that adding viruses to the scope
for ARESupa will also significantly augment its utility as an aid
in the differential diagnosis of viral and bacterial
infections.”
###
About ARESupa Universal Pathogenome Assay
Information on antibiotic susceptibility of
pathogens is of utmost importance for clinical practice,
epidemiology and public health purposes as well as for the
development of pharmaceutical products in the infectious disease
sector. Ares Genetics therefore has developed a molecular
Antibiotic Susceptibility Test (AST) that is marketed under the
brand name ARESupa – Universal Pathogenome Assay and is capable of
accurately identifying microbial pathogens as well as predicting
antibiotic susceptibility via artificial intelligence-powered
interpretation of high-throughput DNA sequencing data obtained by
next-generation sequencing technologies.
ARESupa is based on whole-genome sequencing of
bacterial strains isolated from clinical specimens, combined with
data analysis and interpretation powered by ARESdb, Ares Genetics’
unique, proprietary reference database on genetic antimicrobial
resistance markers. ARESdb covers genomes of about 40,000 bacterial
strains and associated susceptibility data for more than 100
different antibiotics.
ARESupa already today accurately detects
antibiotic susceptibility broadly across drug/pathogen combinations
with prediction algorithms for further drug/pathogen combinations
in development.
The test is initially offered for non-diagnostic
applications in epidemiology, infection control, and outbreak
analysis for customers in the public health sector and the
pharmaceutical industry. A laboratory-developed test (LDT) on
native patient samples for human diagnostic use in indications in
which current culture-based diagnostic practice is inherently
challenging is planned. Furthermore, Ares Genetics has recently
entered into a multi-phase strategic partnership with an
undisclosed leading global in vitro diagnostics corporation to
jointly develop diagnostic solutions for infectious disease testing
based on the ARESupa.
For further information and quotes, please register on the Ares
Genetics cloud platform:
https://ares-genetics.cloud/
or contact
Ares Genetics GmbHKarl-Farkas-Gasse 18A-1030
WienAustriaEmail: services@ares-genetics.com
About Curetis and Ares Genetics
Curetis N.V.’s (Euronext: CURE) goal is to
become a leading provider of innovative solutions for molecular
microbiology diagnostics designed to address the global challenge
of detecting severe infectious diseases and identifying antibiotic
resistances in hospitalized patients.
Curetis’ Unyvero System is a versatile, fast and
highly automated molecular diagnostic platform for easy-to-use,
cartridge-based solutions for the comprehensive and rapid detection
of pathogens and antimicrobial resistance markers in a range of
severe infectious disease indications. Results are available within
hours, a process that can take days or even weeks if performed with
standard diagnostic procedures, thereby facilitating improved
patient outcomes, stringent antibiotic stewardship and
health-economic benefits. Unyvero in vitro diagnostic (IVD)
products are marketed in Europe, the Middle East, Asia and the
U.S.
Curetis’ wholly owned subsidiary Ares Genetics
GmbH is developing next-generation solutions for infectious disease
diagnostics and therapeutics. The ARES Technology Platform combines
the presumably most comprehensive database worldwide on the
genetics of antimicrobial resistances, ARESdb, with advanced
bioinformatics and artificial intelligence.
For further information, please visit
www.curetis.com and www.ares-genetics.com.
About BGI Group
Founded in 1999, BGI is one of the world's
leading life science and genomics organizations. BGI’s mission is
to use genomics to benefit mankind and to be a leader in the era of
life sciences. BGI follows a genomics development model of
“research, production and application”. With businesses
in more than 100 countries and regions around the world, BGI
has established cooperation and partnerships with thousands of
different organizations across multi-disciplinary research areas
including medical health, resource conservation and judicial
services. At the same time, BGI provides equipment, technical
support and solutions for the needs of national economies and
people's livelihoods, such as precision medicine and precision
health. BGI is committed to applying its genetic and technological
achievements to real world settings in order to realize the dream
of trans-omics for a better life.
About MGI
MGI Tech Co., Ltd. (referred to as MGI) is
committed to building core tools and technology to lead life
science through intelligent innovation. MGI focuses on R&D,
production and sales of DNA sequencing instruments, reagents, and
related products to support life science research, agriculture,
precision medicine and healthcare. MGI is a leading producer of
clinical high-throughput gene sequencers, and its multi-omics
platforms include genetic sequencing, mass spectrometry, medical
imaging, and laboratory automation.
Founded in 2016, MGI has more than 1,000
employees, nearly half of whom are R&D personnel. MGI operates
in 26 countries and regions and has established multiple research
and production bases around the world. Providing real-time,
comprehensive, life-long solutions, its vision is to enable
effective and affordable healthcare solutions for all.
Legal Disclaimer
This document constitutes neither an offer to
buy nor to subscribe securities and neither this document nor any
part of it should form the basis of any investment decision in
Curetis.
The information contained in this press release
has been carefully prepared. However, Curetis bears and assumes no
liability of whatever kind for the correctness and completeness of
the information provided herein. Curetis does not assume an
obligation of whatever kind to update or correct information
contained in this press release whether as a result of new
information, future events or for other reasons.
This press release includes statements that are,
or may be deemed to be, “forward-looking statements”. These
forward-looking statements can be identified by the use of
forward-looking terminology, including the terms “believes”,
“estimates”, “anticipates”, “expects”, “intends”, “may”, “will”, or
“should”, and include statements Curetis makes concerning the
intended results of its strategy. By their nature, forward-looking
statements involve risks and uncertainties and readers are
cautioned that any such forward-looking statements are not
guarantees of future performance. Curetis’ actual results may
differ materially from those predicted by the forward-looking
statements. Curetis undertakes no obligation to publicly update or
revise forward-looking statements, except as may be required by
law.
Curetis Group Contact Details
Curetis GmbHMax-Eyth-Str.
4271088 Holzgerlingen, GermanyTel. +49 7031 49195-10pr@curetis.com
or ir@curetis.comwww.curetis.com
Ares Genetics
GmbHKarl-Farkas-Gasse 18A-1030 WienAustriaTel. +43 1 361
8880 10contact@ares-genetics.com www.ares-genetics.com
Curetis Group International Media &
Investor Inquiries
akampionDr. Ludger Wess / Ines-Regina
ButhManaging Partnersinfo@akampion.comTel. +49 40 88 16 59 64Tel.
+49 30 23 63 27 68
- 20200130_Ares_BGI-MGI_CoronaVirus_final_approved
Direxion Daily Healthcar... (AMEX:CURE)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
Direxion Daily Healthcar... (AMEX:CURE)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024
